Gemtesa (vibegron) is not an anticholinergic. It belongs to a completely different drug class called beta-3 adrenergic agonists. While both types of medication treat overactive bladder, they work through separate biological pathways, and the distinction matters because it translates into a very different side effect profile.
How Gemtesa Works Differently
Anticholinergic medications for overactive bladder, such as oxybutynin and solifenacin, work by blocking a chemical messenger called acetylcholine. This reduces involuntary bladder contractions, but acetylcholine is active throughout the body, including the brain, eyes, gut, and salivary glands. Blocking it in those areas is what causes the well-known side effects: dry mouth, constipation, blurred vision, and cognitive fog.
Gemtesa takes a different route entirely. It activates beta-3 adrenergic receptors on the bladder muscle, which directly relaxes the muscle wall and increases bladder capacity. The result is fewer episodes of urgency and frequency without interfering with acetylcholine signaling. Because these beta-3 receptors are concentrated in the bladder, the drug’s effects are more targeted.
Side Effects Compared to Anticholinergics
The practical payoff of not being anticholinergic shows up clearly in clinical trial data. In a head-to-head comparison, dry mouth occurred in just 1.8% of patients taking Gemtesa 75 mg, compared to 5.2% on the anticholinergic tolterodine. With other anticholinergics, dry mouth rates climb dramatically: up to 90% with some medications. Constipation and blurred vision were reported in fewer than 5% of Gemtesa patients across trials, while anticholinergics produced constipation in 7.7% to 65% and blurred vision in 3.8% to 35%, depending on the specific drug.
This gap is large enough that the American Urological Association specifically notes that beta-3 agonists “appear to have lower rates of common side effects” and recommends switching to one if a patient finds anticholinergic side effects intolerable.
Cognitive Safety in Older Adults
One of the biggest concerns with anticholinergic medications is their effect on the brain. Long-term use has been linked to increased risk of cognitive decline and dementia, particularly in older adults. This happens because many anticholinergics cross the blood-brain barrier and interfere with brain signaling.
Preclinical studies confirmed that Gemtesa does not cross the blood-brain barrier and does not enter the central nervous system. This makes it a notably safer option for elderly patients or anyone concerned about cognitive function. It’s one of the primary reasons clinicians have shifted toward beta-3 agonists for older populations.
Blood Pressure Effects
Because Gemtesa activates adrenergic receptors, a reasonable concern is whether it raises blood pressure. Clinical trial data from ambulatory blood pressure monitoring found no meaningful effect. The difference between Gemtesa and placebo in daytime systolic blood pressure was just 0.8 mmHg, and the difference in diastolic pressure was essentially zero. Heart rate increased by less than 1 beat per minute. None of these differences were statistically significant or clinically relevant.
Where Gemtesa Fits in Treatment
The American Urological Association and the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction give anticholinergics and beta-3 agonists equal standing as first-line medication options for overactive bladder. Their guidelines rate this as a strong recommendation based on the highest level of evidence, noting that the two classes show similar effectiveness for reducing urgency, frequency, and incontinence episodes.
The guidelines also outline several scenarios where Gemtesa’s drug class has a specific role. If you’ve tried an anticholinergic and couldn’t tolerate the side effects, switching to a beta-3 agonist is a recommended next step. For patients who don’t get enough relief from a single medication, combining a beta-3 agonist with an anticholinergic is another option. And for men who have both overactive bladder and an enlarged prostate, beta-3 agonists are recommended either alone or alongside other prostate medications.
Gemtesa is FDA-approved for adults with overactive bladder symptoms, including urge incontinence, urgency, and urinary frequency. It also carries a specific indication for adult men taking medication for benign prostatic hyperplasia, making it one of few OAB drugs with that dual approval.